Healthcare & Pharmaceuticals
Novel in vivo Wnt/b-catenin drug screening technology
We use early zebrafish development as a readout of potential Wnt/b-catenin inhibitors. By activating the pathway at the level of GSK3 at 5 hours post fertilization, we seek inhibitors that act at the level of, or below, the b-catenin destruction complex. The entire assay is completed in 24 hours. In addition to identifying Wnt/b-catenin inhibitors we also simultaneously screen for toxicity and potential off target developmental defects.
